Results 101 to 110 of about 19,249 (228)

Suprachoroidal Hemorrhage with Delayed Rebleeding as the First Presentation of Bullous Pemphigoid Associated Acquired Hemophilia [PDF]

, 2016
published_or_final_versio
Choy, NKB, Lai, JSM, Mak, KHA, Ng, LKA, Shum, JWH   +4 more
core   +1 more source

Future directions in acquired hemophilia A [PDF]

Blood, 2021
Siragusa, Sergio, Napolitano, Mariasanta
openaire   +3 more sources

Dual‐Functional Polyphosphoesters for Gene Delivery: Synergistic Effects of Guanidinium and Hydrophobic Side Chains in Degradable Polymers

Advanced Healthcare Materials, Volume 15, Issue 9, 6 March 2026.
This study presents guanidinium‐ and indole‐functionalized polyphosphoesters as degradable, non‐viral gene delivery vectors. Through precise tuning of charge density and hydrophobicity, these polymers form stable polyplexes with low toxicity. Remarkably, minor structural changes yield up to 200‐fold differences in transfection efficiency, highlighting ...
Markus Kötzsche, Andreas Dzierza, Jan Egger, Timo Rheinberger, Christin Weilandt, Frederik R. Wurm, Ivo Nischang, Dagmar Fischer, Kalina Peneva   +8 more
wiley   +1 more source

Hemofilia A adquirida Acquired hemophilia A

Revista Cubana de Hematología, Inmunología y Hemoterapia, 2010
La hemofilia A adquirida (HAA) es un trastorno hemorrágico poco frecuente caracterizado por la presencia de autoanticuerpos contra el factor VIII (FVIII) circulante.
Delfina Almagro Vázquez
doaj  

Factor XIII Deficiency: A Silent Bleeder Behind a Normal Coagulation Profile

Clinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT Factor XIII deficiency is a rare cause of bleeding disorder. An 8‐month‐old male infant presented with persistent bleeding from a minor lip cut injury, which was sustained 2 days prior. The bleeding did not stop despite local hemostatic measures.
Ramesh Yadav, Madhav Raj Karki, Dikshya Pokhrel, Aron Neupane, Kshitiz Parajuli, Hem Sagar Rimal   +5 more
wiley   +1 more source

The changing landscape of treatment for acquired hemophilia A

Bleeding, Thrombosis and Vascular Biology
Acquired hemophilia A (AHA) is a rare acquired autoimmune disorder caused by autoantibodies against coagulation factor VIII (FVIII), which cause a hemorrhagic diathesis, not rarely of severe degree.
Massimo Franchini, Daniele Focosi
doaj   +1 more source

Patients' Associations as Co‐Creators of Knowledge: Insights From a Community‐Based Participatory Research Study (ProSafe Project)

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims Patient and public involvement and engagement (PPIE) in research is crucial for producing knowledge that is meaningful to the participating community. Sharing PPIE principles into practical tools and strategies enriches the development of participatory research methodologies.
Francesca Moretti, Silvia Colpo, Sara Montresor, Daniela Facchinello, Raffaella Robello, Mariangela Mazzi, Stefano Tardivo, Lisa Stagi, Luisa De Stefano, Andrea Zotti, Luigi Ambroso, Cristina Destro, Salvo Leone, Davide Petruzzelli, Ugo Moretti, Michela Rimondini   +15 more
wiley   +1 more source

Acquired Factor VIII Inhibitors: Three Cases

Turkish Journal of Hematology, 2013
Acquired hemophilia A is a rare, but devastating bleeding disorder caused by spontaneous development of autoantibodies directed against coagulation factor VIII.
Tay Za Kyaw, S. Jayaranee, Ping Chong Bee, Edmund Fui Min Chin   +3 more
doaj   +1 more source

Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Companion diagnostics use biomarker‐based assays to stratify patients for precision therapies, improving outcomes while reducing ineffective treatment and side effects. This review summarizes the evolution, regulatory landscape, clinical applications, and technological platforms of CDx, highlighting their role in biomarker‐driven precision therapy.
Yuesong Wu, Rou Xue, Xiangwen Luo, Jiangnan Liao, Zongbo Zhang, Jinhai Deng, Teng Liu, Xin Li, Zhe‐Sheng Chen, Mingzhu Yin   +9 more
wiley   +1 more source

Acceptability and Determinants for Implementation of the EnzySystem, a Novel Near‐Patient Testing Platform for Haemophilia A

Haemophilia, Volume 32, Issue 2, Page 481-489, March/April 2026.
ABSTRACT Introduction Coagulation testing in haemophilia A is limited by the scarcity of testing facilities capable of performing relevant assays. This issue incentivized the development of the EnzySystem for haemophilia A, a near‐patient testing platform aimed to measure Factor VIII activity and thrombin generation simultaneously within 1 h from 100 ...
Aernoud P. Bavinck, Kyle Davis, Lisa van Engelshoven, Monique G. van Lier, Tanja Hamacher, Nicole M. A. Blijlevens, Amy Shapiro, Saskia E. M. Schols, Waander L. van Heerde   +8 more
wiley   +1 more source